Circulating IGF-1, IGFB-3, GH and TSH levels in multiple sclerosis and their relationship with treatment

References

• Lassmann H. Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci. 2013;333:1–4.10.1016/j.jns.2013.05.010
   PubMed Web of Science ®Google Scholar
• Harvey AR, Kendall CL, Sykova E. The status and organization of astrocytes, oligodendroglia and microglia in grafts of fetal rat cerebral cortex. Neurosci Lett. 1997;228:58–62.10.1016/S0304-3940(97)00341-8
   PubMed Web of Science ®Google Scholar
• Gveric D, Cuzner ML, Newcombe J. Insulin-like growth factors and binding proteins in multiple sclerosis plaques. Neuropathol Appl Neurobiol. 1999;25:215–225.10.1046/j.1365-2990.1999.00187.x
   PubMed Web of Science ®Google Scholar
• Clark R. The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and immune function. Endocr Rev. 1997;18:157–179.10.1210/edrv.18.2.0296
   PubMed Web of Science ®Google Scholar
• Dubois-Dalcq M, Murray K. Why are growth factors important in oligodendrocyte physiology. Pathol Biol (Paris). 2000;48:80–86.
   PubMed Web of Science ®Google Scholar
• McMorris F, Smith T, DeSalvo S. Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte development. Proc Natl Acad Sci USA. 1986;83:822–826.10.1073/pnas.83.3.822
   PubMed Web of Science ®Google Scholar
• Ajo R, Cacicedo L, Navarro C, et al. Growth hormone action on proliferation and differentiation of cerebral cortical cells from fetal rat. Endocrinology. 2003;144:1086–1097.10.1210/en.2002-220667
   PubMed Web of Science ®Google Scholar
• Schneider H, Pagotto U, Stalla G. Central effects of the somatotropic system. Eur J Endocrinol. 2003;149:377–392.10.1530/eje.0.1490377
   PubMed Web of Science ®Google Scholar
• Ozawa K, Suchanek G, Breitschopf H, et al. Patterns of oligodendroglia pathology in multiple sclerosis. Brain. 1994;117:1311–1322.10.1093/brain/117.6.1311
   PubMed Web of Science ®Google Scholar
• Prineas J, Kwon E, Goldenberg P, et al. Multiple sclerosis: oligodendrocyte proliferation and differentiation in fresh lesions. Lab Invest. 1989;61:489–503.
   PubMed Web of Science ®Google Scholar
• Rogister B, Ben-Hur T, Dubois-Dalcq M. From neural stem cells to myelinating oligodendrocytes. Mol Cell Neurosci. 1999;14:287–300.10.1006/mcne.1999.0790
   PubMed Web of Science ®Google Scholar
• Miell JP, Zini M, Quin JD, et al. Reversible effects of cessation and recommencement of thyroxine treatment on insulin-like growth factors (IGFs) and IGF-binding proteins in patients with total thyroidectomy. J Clin Endocrinol Metab. 1994;79:1507–1512.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58:840–846.10.1002/(ISSN)1531-8249
   PubMed Web of Science ®Google Scholar
• Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci. 2008;9:839–855.10.1038/nrn2480
   PubMed Web of Science ®Google Scholar
• Imitola J, Makhlouf T, Khoury SJ. Role of neural stem and oligodendrocyte progenitor cells in demyelinating diseases: insights into disease mechanisms and therapeutic potential; Disorders of myelin in the central and peripheral nervous system. Dangond F, editor. Woburn (MA): Butterworth Heinemann; 2002. p. 57–81.
   Google Scholar
• Mason JL, Ye P, Suzuki K, et al. Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination. J Neurosci. 2000;20:5703–5708.
   PubMed Web of Science ®Google Scholar
• Yao D, Liu X, Hudson LD, et al. Insulin-like growth factor-I given subcutaneously reduces clinical deficits, decreases lesion severity and upregulates synthesis of myelin proteins in experimental autoimmune encephalomyelitis. Life Sci. 1996;58:1301–1306.10.1016/0024-3205(96)00095-1
   PubMed Web of Science ®Google Scholar
• Liu X, Mashour GA, Webster HF, et al. Basic FGF and FGF receptor 1 are expressed in microglia during experimental autoimmune encephalomyelitis: temporally distinct expression of midkine and pleiotrophen. Glia. 1998;24:390–397.10.1002/(ISSN)1098-1136
   PubMed Web of Science ®Google Scholar
• Carson MJ, Behringer RR, Brinster RL, et al. Insulin-like growth factor 1 increases brain growth factor and central nervous system myelination in transgenic mice. Neuron. 1993;10:29–740.
   Web of Science ®Google Scholar
• Warburton C, Powell- Braxton L. Mouse models of IGF-1 deficiency generated by gene targeting. Receptor. 1995;5:35–41.
   PubMedGoogle Scholar
• Torres- Aleman I, Barrios V, Berciano J. The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis. Neurology. 1998;50:772–776.10.1212/WNL.50.3.772
   PubMed Web of Science ®Google Scholar
• Wilczak N, Schaaf M, Bredewold R, et al. Insulin-like growth factor system in serum and cerebrospinal fluid in patients with multiple sclerosis. Neurosci Lett. 1998;257:168–170.10.1016/S0304-3940(98)00829-5
   PubMed Web of Science ®Google Scholar
• Wilczak N, Ramsaransing GSM, Mostert J, et al. Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis. Mult Scler J. 2005;11:13–15.10.1191/1352458505ms1123oa
   PubMed Web of Science ®Google Scholar
• Cannella B, Pitt D, Capello E, et al. Insulin-like growth factor-1 fails to enhance central nervous system myelin repair during autoimmune demyelination. Am J Pathol. 2000;157:933–943.10.1016/S0002-9440(10)64606-8
   PubMed Web of Science ®Google Scholar
• O’Leary MT, Hinks GL, Charlton HM, et al. Increasing local levels of IGF-I mRNA expression using adenoviral vectors does not alter oligodendrocyte remyelination in the CNS of aged rats. Mol Cell Neurosci. 2002;19:32–42.10.1006/mcne.2001.1062
   PubMed Web of Science ®Google Scholar
• Frank JA, Richert N, Lewis B, et al. A pilot study of recombinant insulin-like growth factor-1 in seven multiple sclerosis patients. Mult Scler. 2002;8:24–29.
   PubMed Web of Science ®Google Scholar
• Hosback S, Hardiman O, Nolan CM, et al. Circulating insulin, like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis. Growth Horm IGF Res. 2007;17:472–479.10.1016/j.ghir.2007.06.002
   PubMed Web of Science ®Google Scholar
• Anguela XM, Tafuro S, Roca C, et al. Nonviral-mediated hepatic expression of IGF-I increases treg levels and suppresses autoimmune diabetes in mice. Diabetes. 2013;62:551–560.10.2337/db11-1776
   PubMed Web of Science ®Google Scholar
• Modric T, Silha JV, Shi Z, et al. Phenotypic manifestations of insulin-like growth factor binding protein-3 overexpression in transgenic mice. Endocrinology. 2001;142:1958–1967.
   PubMed Web of Science ®Google Scholar
• Kim HS. Role of insulin-like growth factor binding protein-3 in glucose and lipid metabolism. Ann Pediatr Endocrinol Metab. 2013;18:9–12.10.6065/apem.2013.18.1.9
   PubMedGoogle Scholar
• Johnson MA, Firth SM. IGFBP-3: a cell fate pivot in cancer and disease. Growth Horm IGF Res. 2014;24:164–173.10.1016/j.ghir.2014.04.007
   PubMed Web of Science ®Google Scholar
• Gveric D, Cuzner ML, Newcombe J. Insulin-like growth factors and binding proteins in multiple sclerosis plaques. Neuropathol Appl Neurobiol. 1999;25:215–225.10.1046/j.1365-2990.1999.00187.x
   PubMed Web of Science ®Google Scholar
• Poljakovic Z, Zurak N, Brinar V, et al. Growth hormone and insulin growth factor – I levels in plasma and cerebrospinal fluid of patients with multiple sclerosis. Clin Neurol Neurosurg. 2006;108:255–258.10.1016/j.clineuro.2005.11.014
   PubMed Web of Science ®Google Scholar
• Baas D, Legrand C, Samarut J, et al. Persistence of oligodendrocyte precursor cells and altered myelination in optic nerve associated to retina degeneration in mice devoid of all thyroid hormone receptors. Proc Natl Acad Sci USA. 2002;99:2907–2911.10.1073/pnas.052482299
   PubMed Web of Science ®Google Scholar
• van Dam PS, Aleman A. Insulin-like growth factor-I, cognition and brain aging. Eur J Pharmacol. 2004;490:87–95.10.1016/j.ejphar.2004.02.047
   PubMed Web of Science ®Google Scholar
• Chesik D, De Keyser J, Glazenburg L, et al. Insulin-like growth factor binding proteins: regulation in chronic active plaques in multiple sclerosis and functional analysis of glial cells. Eur J Neurosci. 2006;24:1645–1652.10.1111/ejn.2006.24.issue-6
   PubMed Web of Science ®Google Scholar
• Chesık D, Dekeyser J, Wılczak N. Insulin-like growth factor binding protein-2 as a regulator of IGF actions in CNS: implications in multiple sclerosis. Cytokine Growth Factor Rev. 2007;18:267–278.10.1016/j.cytogfr.2007.04.001
   PubMed Web of Science ®Google Scholar